Desperately seeking…Models to find the right partner and the best use for checkpoint inhibitors

Area of Science:

• Oncology
• Immunology
• Pharmacology

Background:

• Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy, demonstrating significant clinical activity across numerous cancer types.
• However, a substantial proportion of patients do not respond to ICIs, highlighting the need for improved treatment strategies.

Discussion:

• Preclinical studies suggest synergistic effects when combining ICIs with other therapeutic modalities, including targeted drugs, chemotherapy, and radiotherapy.
• Identifying the most effective combinatorial regimens and specific disease settings is crucial for maximizing patient benefit.

Key Insights:

• The clinical success of ICIs is limited to a subset of patients.
• In vivo studies indicate potent synergies between ICIs and other cancer treatments.

Outlook:

• Development of predictive models is essential for selecting optimal combination therapies.
• Future research should focus on personalized combinatorial approaches to enhance ICI efficacy in broader patient populations.